The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Triggering global regulatory submissions this year for the treatment of obesity
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Subscribe To Our Newsletter & Stay Updated
